Fraunhofer ITEM

Stefanie Scheffler, Patricia Mattis, #PariaPajouhiPaad, BILLY D. MONTHE T., Christopher Krückemeier – the next big step towards market readiness of EVape has been achieved 💪. Congratulations on entering Phase 2 of the Fraunhofer AHEAD program. What a fantastic team – very well deserved 🎉! Fitting to this success, the current issue of the Fraunhofer magazine features an in-depth article on this promising project: 'Improving Safety for Vapers.' Highly recommended reading! 🌐https://lnkd.in/eNBkVVWr #riskassessment #safetyassessment #vaping #eliquids Fraunhofer-Gesellschaft

The presentation of the poster awards was a wonderful conclusion of our first CIMD Symposium on "RNA-Based Therapeutics." 🥳 Congratulations to the three poster award winners 🥳: 🏆Elisa Mohr: “Cardiovascular diseases in 3D: Human organoids as a multipurpose tool to recapitulate cardiac pathophysiology in vitro” 🏆Philipp Höhne: “Superparamagnetic nanoparticles as cardiac-targeted delivery tools for ncRNA therapeutics” 🏆Clara Gebhardt: “Optimizing and scaling up mRNA-based CAR-T cell generation using lipid nanoparticles” Your dedication and groundbreaking work are shaping the future of RNA-based therapeutics. Elisa Mohr and Christian Bär, we are thrilled that you are advancing the critically important topic of #organoid development with us here at Fraunhofer ITEM (⬆️ poster prize above). The development of #3D human cardiac organoid (#hCO) models constitute a significant advancement in cardiovascular research. By combining multiple cell types such as cardiomyocytes, fibroblasts and endothelial cells, the hCO mimics the human heart's complexity and function, offering a valuable tool for studying heart diseases and testing new drugs in a more relevant environment. This is especially important as cardiovascular diseases are expected to rise in the coming years, demanding reliable In-vitro models for drug discovery and development. We can’t wait to see what’s next 💪! A big thank you to all supporters and contributors! #RNAresearch #RNAtherapeutics #CardiacOrganoids #DiseaseModelling #DrugDiscovery

Why is research on #RNAbased therapeutics so important?   1️⃣Rapid and flexible development 2️⃣Wide and growing range of applications of RNA for vaccines and therapeutics 3️⃣Precise and targeted delivery needed 4️⃣Enabling personalized medicine 5️⃣Fewer side effects than “conventional gene therapy”   These are excellent reasons to intensify research in this field within the "RNA Therapeutics" platform of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases #CIMD, but also here at Fraunhofer ITEM. We are currently placing particular emphasis on the identification of novel #RNAdrugcandidates, the further development of our 3D #invitroplatform and nanoparticle based #deliverysystems for RNA therapeutics. We are pleased that so many scientists who are advancing this research area have found their way to Hannover today to join us at our very first symposium on "RNA-Based Therapeutics" and to discuss their ideas and projects with us 🎉🙏. We are excited to share some highlights with all of you and are eagerly anticipating today’s evening. We are keeping our fingers crossed for all the poster authors regarding the poster award ceremony 🤞. #RNAresearch #RNAtherapeutics #Hannover

👨🔬🔬💼 Stefan Bol has been working as a Biological Technical Assistant at Fraunhofer ITEM since October 15, 2021. Driven by the motivation to contribute directly to health research and to improve the quality of life for patients, he chose to pursue a career as a BTA in biomedical engineering. 🚀 His work at Fraunhofer ITEM allows him to operate in an environment that is deeply engaged in researching innovative medical inhalation systems and advanced implant systems. He is particularly fascinated by the combination of basic research, industrial application, and clinical practice that takes place at Fraunhofer ITEM. 🌿 In his free time, Stefan enjoys spending time in nature, whether through physical activities or simply going for walks. A successful day for him includes productive work on projects, positive interpersonal interactions with the team, and time for personal interests. 🔗 Read Stefan’s full portrait on our careers page: https://lnkd.in/eqAyCdZQ #yourITEMjob #fraunhoferitem #wearefraunhofer #careeratfraunhofer #gettingtoknowtheteam #translationalbiomedicalengineering

Chemical Safety goes Next Generation Risk Assessment (#NGRA): Throughout our lives, we are constantly exposed to chemicals. To ensure our safety, #riskassessment is essential – and for decades, this has relied on animal testing. But times are changing! At @Fraunhofer ITEM, our scientists are actively shaping the paradigm shift towards Next Generation Risk Assessment, moving away from animal testing and towards safer, more effective, and sustainable methods. 🔬🧫🖥️By utilizing advanced in-vitro, ex-vivo, and in-silico methods, we are developing innovative, animal-free strategies that better predict chemical risks for humans. These new approach methodologies (#NAMs) are driving the future of toxicology and risk assessment. 📹 To learn more about these cutting-edge approaches to chemical safety, you can find a more detailed version of the video here: https://lnkd.in/ewKQ3JxQ #chemicalsafety #toxicology #AnimalFreeTesting

Exciting updates from the #ZeroPM project! Last week at the ZeroPM Workshop "Achieving Zero Pollution of Persistent and Mobile Substances: Prioritization through Substance Grouping and Risk Assessment" in Dessau, Fraunhofer scientists contributed valuable insights towards regulating persistent and mobile compounds. Abishek Laxmanan Ravi Shankar presented #PBKmodeling approaches to estimate human thresholds for these substances, while Dr. Sylvia. Escher introduced a risk matrix that integrates #exposure and #toxicity data into the prioritization process. This workshop facilitated a lively exchange of ideas between scientists, regulatory authorities, and industry stakeholders. A great milestone in translating research into action! 💡 🚰 In the second ZeroPM workshop, experts discussed prioritization strategies for preventing and removing PMT/vPvM substances, with a special focus on human exposure via drinking water. Key speakers from UBA, ECHA, the European Commission, and innovators presented alongside ZeroPM researchers to address the challenges of substance prioritization. #ZeroPM is committed to developing a science-driven, multi-stakeholder framework to advance the Chemicals Strategy for Sustainability (CSS), targeting a toxic-free environment. The project partners are working to prevent the negative impacts of PMT/vPvM substances, like mobile #PFAS, while fostering innovation for a safer society. 🌍 #riskassessment #zeropollution

🎉Congratulations to Charline Sommer & Maximilian Schinke – both were awarded the Young Scientist Travel Award #YSTA at the #EUSAAT Congress last week🎉. 🏆Maximilian received the award for his presentation titled 'Generation of Human Sensory Macrophages to Replace Animal Research in Preclinical Pharmacology and Drug Safety Applications' – a very exciting and new topic for us at Fraunhofer ITEM: 💡The use of innovative macrophages derived from induced pluripotent stem cells (#iPSC) represents a promising approach to evaluate new therapeutic strategies and conduct a comprehensive #safetyassessment of parenteral drugs. Particularly regarding this safety assessment, we could provide a promising alternative that significantly advances the Monocyte Activation Test (#MAT), making the use of rabbits or horseshoe crabs in the field of parenteral drugs unnecessary. 🏆Charline was awarded for the abstract of her poster, developed in the context of the imSAVAR project, on 'Immune-related adverse outcome pathways' (irAOPs), and this is what it was about: 💡 Immune therapies are promising but are associated with side effects – often with unresolved pathophysiological mechanisms. The #irAOP concept helps to focus on key cells and molecules inducing the adverse effects and uncovers knowledge gaps in the immunological cascade. This allows targeted generation of experiments to fill gaps and verify the irAOPs, supporting safe application of #immunetherapies. #verywelldeserved

On September 25 and 26, 2024, the #DGMet annual meeting will take place at Rauischholzhausen Castle, near Marburg. As always, it will be hosted by the Deutsche Gesellschaft für Metabolomforschung (DGMet). Fraunhofer ITEM is represented by Dr. Sven Schuchardt, Head of Department of Bio- and Environmental Analytics, who is a founding member of the DGMet and the society's treasurer. Founded in 2019, the DGMet aims to promote research in the field of metabolomics and to act as an interaction platform for scientists in the field. It does so through their annual conference, but it also plays a pivotal role in fostering the growth of #metabolomeresearch through various other initiatives such as the organization of specialized workshops and an educational program designed to enhance knowledge transfer, technology sharing, and the development of standardized protocols in metabolome research. Together with his team at Fraunhofer ITEM, Sven Schuchardt is making an important contribution to the advancement of metabolomics research in Germany. Find out more about the DGMet and their annual meeting here: https://lnkd.in/eEm367Xz #DGMet #metabolomics #bioanalytics #environmentalanalytics

📢Today: ⏰Last opportunity to register for the symposium “RNA-Based Therapeutics“ (September 30, CRC Hannover, DE)! Do you need arguments for a last-minute registration⁉️🙂 Here are some convincing 🔎insights into the program: ⏲️ 11: 45 Welcome Norbert Krug and Christian Bär, Fraunhofer ITEM 12:00 noon – 1:00 p.m. ▶️ Session 1: Target discovery and lead optimization Chaired by Lena Wiese, Fraunhofer ITEM / GU Frankfurt 1:00 p.m. – 2:00 p.m. ▶️Session 2: Advanced human preclinical models Chaired by Katherina Sewald, Fraunhofer ITEM ➕2:00 p.m. – 2:30 p.m. Poster viewing I 2:30 p.m. – 3:30 p.m. 👉Special Session (I): Innovations towards clinical application Chaired by Christian Bär, Fraunhofer ITEM / Hannover Medical School 3:30 p.m. – 4:50 p.m. ▶️Session 3: Targeted delivery strategies Chaired by Jan Fiedler, Fraunhofer ITEM ➕4:50 p.m. – 5:20 p.m. Poster viewing II 5:20 p.m. – 6:00 p.m. ▶️Session 4: RNA clinical development Chaired by Christian Bär, Fraunhofer ITEM / Hannover Medical School 6:00 p.m. – 7:00 p.m. 👉Special Session (II): Industry perspective Chaired by Ruben R. Rosencrantz, Fraunhofer IAP 7:00 p.m. – 8:00 p.m. ▶️Evening session with poster viewing and poster award ceremony 🔬Details on the program and the registration are available on our🌐 website: https://lnkd.in/eFA7TvmP We look forward to seeing you in Hannover on 📅September 30!🙂

🌟 Herzlich Willkommen an unsere neuen Kolleginnen und Kollegen! 🌟 Gestern durften wir am Fraunhofer ITEM einige neue Mitarbeiterinnen und Mitarbeiter bei unserer Onboarding-Veranstaltung begrüßen - darunter viele junge Menschen, die bei uns ihre Ausbildung beginnen oder ein Freiwilliges Wissenschaftliches Jahr absolvieren. Institutsleiter Prof. Norbert Krug stellte das Institut und seine Forschungsschwerpunkte vor und auf einem kleinen »Marktplatz« gab es die Gelegenheit, Teams und Initiativen, aber auch sich gegenseitig kennenzulernen. Wir wünschen allen neuen Kolleginnen und Kollegen einen guten Start am Fraunhofer ITEM! Wir freuen uns sehr, dass wir für viele von euch sogar der »Start ins Berufsleben« sind 🚀☺️! #Willkommen #Onboarding #Forschung #Hannover #yourITEMjob #pioneersforsustainablehealth